From tyrian purple to kinase modulators: Naturally halogenated indirubins and synthetic analogues

Planta Medica

Volumn 78, Issue 14, 2012, Pages 1515-1528

  Vougogiannopoulou, Konstantina ^a   Skaltsounis, Alexios Leandros ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Bolinus brandaris; CDKs; GSK 3 ; Hexaplex trunculus; indigo; Indirubin; Muricidae; protein kinases; stem cells; Tyrian purple

Indexed keywords

5 BROMOINDIRUBIN 3' OXIME; 5 CARBOXYINDIRUBIN; 6 BROMOINDIRUBIN; 6 BROMOINDIRUBIN 3' OXIME; 6 BROMOISATIN; 7 BROMOINDIRUBIN 3' OXIME; AURORA A KINASE; AURORA B KINASE; AURORA C KINASE; BROMINE DERIVATIVE; CD135 ANTIGEN; CYCLIN B; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 5; CYCLIN E; DYE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; HALOGENATED HYDROCARBON; INDIRUBIN; INDIRUBIN 3' OXIME; INDIRUBIN 5 SULFONATE; JANUS KINASE; PROTEIN KINASE; PROTEIN P35; TYRIAN PURPLE; TYRINDOLENINONE; TYRIVERDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; BACTERIOSTASIS; DRUG CYTOTOXICITY; DRUG ISOLATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; HEART MUSCLE CELL; HUMAN; KIDNEY CELL; LEUKEMIA; NERVE DEGENERATION; NONHUMAN; PANCREAS CELL; SOLID TUMOR; STEM CELL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BRASSICACEAE; FABACEAE; GASTROPODA; GLYCOGEN SYNTHASE KINASE 3; HALOGENATION; HEART; HUMANS; INDOLES; KIDNEY; LEUKEMIA; NEOPLASMS; NEURODEGENERATIVE DISEASES; PANCREAS; POLYGONUM; PROTEIN KINASE INHIBITORS; STEM CELLS; STRUCTURE-ACTIVITY RELATIONSHIP;

BOLINUS BRANDARIS; HEXAPLEX TRUNCULUS; MURICIDAE; TYRIA;

EID: 84867074848     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0032-1315261     Document Type: Article

References (176)

1. Clark R. JH, Cooksey C. J., Daniels M. AM, Withnall R. Indigo, woad, and Tyrian Purple: important vat dyes from antiquity to the present. Endeavour: 1993; 17 191 199
2. Weston C. H. Observations on the manner of manufacturing indigo in the Southern Provinces of India; with some remarks on its chemical changes and combinations. J Franklin I: 1829; 8 233 240
3. Doménech A., Doménech-Carbó M. T., del Rio M. S., Goberna S., Lima E. Evidence of topological indigo/dehydroindigo isomers in maya blue-like complexes prepared from palygorskite and sepiolite. J Phys Chem C: 2009; 113 12118 12131
4. Ricketts R. Polygonum tinctorium: contemporary indigo farming and processing in Japan. In: Meijer L., Guyard N., Skaltsounis A. L., Eisenbrand G. editors Indirubin, the red shade of indigo. Roscoff, France Life in Progress Editions: 2006; 147 156
5. McGovern P. E., Michel R. H. Royal purple dye: tracing the chemical origins of the industry. Anal Chem: 1985; 57 1514 1522
6. Hoffman R. C., Zilber R. C., Hoffman R. E. NMR spectroscopic study of the Murex trunculus dyeing process. Magn Reson Chem: 2010; 48 892 895
7. Van Elslande E., Lecomte S., Le Ho A. S. Micro-Raman spectroscopy (MRS) and surface-enhanced Raman scattering (SERS) on organic colourants in archaeological pigment. J Raman Spectrosc: 2008; 39 1001 1006
8. March R. E., Papanastasiou M., McMahon A. W., Allen N. S. An investigation of paint from a mural in the church of Sainte Madeleine, Manas, France. J Mass Spectrom: 2011; 46 816 820
9. Dupont C. The dog whelk Nucella lapillus and dye extraction activities from the iron age to the middle ages along the Atlantic coast of France. J Island Coastal Archeol: 2011; 6 3 23
10. Withnall R., Patel D., Cooksey C., Naegel L. Chemical studies of the purple dye of Purpura pansa. Dyes Hist Archaeol: 2003; 19 109 117
11. Wu L. M., Yang Y. P., Zhu Z. H. Studies on the active principles of Indigofera tinctoria in the treatment of CML. Comm Chin Herb Med: 1979; 9 6 8
12. Sato N., Meijer L., Skaltsounis L., Greengard P., Brivanlou A. H. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3 specific inhibitor. Nat Med: 2004; 10 55 63 (Pubitemid 38524699)
13. Leclerc S., Garnier M., Hoessel R., Marko D., Bibb J. A., Snyder G. L., Greengard P., Biernat J., Wu Y. Z., Mandelkow E. M., Eisenbrand G., Meijer L. Indirubin inhibits glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimers disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem: 2001; 276 251 260 (Pubitemid 32050314)
14. Hoessel R., Leclerc S., Endicott J. A., Nobel M. E., Lawrie A., Tunnah P., Leost M., Damiens E., Marie D., Marko D., Niederberger E., Tang W., Eisenbrand G., Meijer L. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin dependent kinases. Nat Cell Biol: 1999; 1 60 67 (Pubitemid 129495012)
15. Myrianthopoulos V., Magiatis P., Ferandin Y., Skaltsounis A. L., Meijer L., Mikros E. An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins. J Med Chem: 2007; 50 4027 4037 (Pubitemid 47301735)
16. Adachi J., Mori Y., Matsui S., Takigami H., Fujino J., Kitagawa H., Miller C. A. 3rd, Kato T., Saeki K., Matsuda T. Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J Biol Chem: 2001; 276 31475 31478
17. Knockaert M., Blondell M., Bach S., Leost M., Elbi C., Hager G. L., Nagy S. R., Han D., Denison M., Ffrench M., Ryan X. P., Magiatis P., Polychronopoulos P., Greengard P., Skaltsounis L., Meijer L. Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins. Oncogene: 2004; 23 4400 4412 (Pubitemid 38850419)
18. Grothaus P. G., Cragg G. M., Newman D. J. Plant natural products in anticancer drug discovery. Curr Org Chem: 2010; 14 1781 1791
19. Schunck E. On the formation of indigo-blue. Part I. Mem Manchester Lit Phil Soc Ser 2: 1855; 2 177 208
20. Maugard T., Enaud E., Choisy P., Legoy M. D. Identification of an indigo precursor from leaves of Isatis tinctoria (Woad). Phytochemistry: 2001; 58 897 904 (Pubitemid 33086215)
21. Guengerich P. F., Martin M. V., McCormick W. A., Nguyen L. P., Glover E., Bradfield C. A. Aryl hydrocarbon receptor response to indigoids in vitro and in vivo. Arch Biochem Biophys: 2004; 423 309 316 (Pubitemid 38328440)
22. Shiao C. C., Weng C. Y., Chuang J. C., Huang M. S., Chen Z. Y. Purple urine bag syndrome: a community-based study and literature review. Nephrology (Carlton): 2008; 13 554 559
23. Cooksey C. J. Tyrian purple: 6,6-dibromoindigo and related compounds. Molecules: 2001; 6 736 769 (Pubitemid 38990283)
24. Oberthür C., Graf H., Hamburger M. The content of indigo precursors in Isatis tinctoria leavesa comparative study of selected accessions and post-harvest treatments. Phytochemistry: 2004; 65 3261 3268 (Pubitemid 39550394)
25. Oberthür C., Schneider B., Graf H., Hamburger M. The elusive indigo precursors in woad (Isatis tinctoria L.)identification of the major indigo precursor, isatan A, and a structure revision of isatan B. Chem Biodivers: 2004; 1 174 182
26. Chen H-J, Tsao H-H, Lo J. G., Chiu K-H, Jen J-F. Supercritical fluid extraction coupled with solvent-less spray collection mode for rapid separation of indirubin and tryptanthrin from Folium Isatidis. Sep Sci Technol: 2011; 46 972 997
27. Friedländer P. Über den Farbstoff des antiken Purpurs aus Murex brandaris. Chem Ber: 1909; 42 765 770
28. Karapanagiotis I., de Villemereuil V., Magiatis P., Polychronopoulos P., Vougogiannopoulou K., Skaltsounis A. L. Identification of the coloring constituents of four natural indigoid dyes. J Liq Chromatogr R T: 2006; 29 1491 1502
29. Baker J. T., Sutherland M. D. Pigments of marine animals. VIII. Precursors of 6,6-dibromoindigotin (Tyrian Purple) from the mollusc Dicathais orbita gmelin. Tetrahedron Lett: 1968; 1 43 46
30. Baker J. T., Duke C. C. Isolation of choline and choline ester salts of tyrindoxyl sulphate from the marine molluscs Dicathais orbita and Mancinella keineri. Tetrahedron Lett: 1976; 15 1233 1234
31. Baker J. T. Tyrian Purple: an ancient dye, a modern problem. Endeavour: 1976; 33 11 17
32. Fujise Y., Miwa K., Ito S. Structure of tyriverdin, the intermediate precursor of Tyrian purple. Chem Lett: 1980; 6 631 632
33. López Chávez F. J., Ríos Chávez P., Oyama K. Brominated precursors of Tyrian purple (C.I. Natural Violet 1) from Plicopurpura pansa, Plicopurpura columellaris, and Plicopurpura patula. Dyes Pigments: 2009; 83 7 13
34. Fouquet H., Bielig H-J. Biological precursors and genesis of tyrian-purple. Angew Chem Int Ed: 1971; 10 816 817
35. Westley C., Benkendorff K. Sex-specific Tyrian purple genesis: precursor and pigment distribution in the reproductive system of the marine mollusc, Dicathais orbita. J Chem Ecol: 2008; 34 44 56
36. Benkendorff K., Bremner J. B., Davies A. R. Tyrian Purple precursors in the egg masses of the australian muricid Dicathais orbita: a possible defensive role. J Chem Ecol: 2000; 26 1037 1050 (Pubitemid 30230490)
37. Benkendorff K., Bremner J. B., Davies A. R. Indole derivatives from the egg masses of Muricid molluscs. Molecules: 2001; 6 70 78 (Pubitemid 38982491)
38. Magiatis P., Skaltsounis A. L. From Hexaplex trunculus to new kinase inhibitory indirubins. In: Meijer L., Guyard N., Skaltsounis A. L., Eisenbrand G. editors Indirubin, the red shade of indigo. Roscoff, France Life in Progress Editions: 2006; 147 156
39. Meijer L., Skaltsounis A. L., Magiatis P., Polychronopoulos P., Knockaert M., Leost M., Ryan X. P., Vonica C. A., Brivanlou A., Dajani R., Crovace C., Tarricone C., Musacchio A., Roe S. M., Pearl L., Greengard P. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol: 2003; 10 1255 1266 (Pubitemid 38050973)
40. Puchalska M., Poeć-Pawlak K., Zadrozna I., Hryszko H., Jarosz M. Identification of indigoid dyes in natural organic pigments used in historical art objects by high-performance liquid chromatography coupled to electrospray ionization mass spectrometry. J Mass Spectrom: 2004; 39 1441 1449 (Pubitemid 39664929)
41. Nowik W., Marcinowska R., Kusyk K., Cardon D., Trojanowicz M. High performance liquid chromatography of slightly soluble brominated indigoids from Tyrian purple. J Chromatogr A: 2011; 1218 1244 1252
42. Benkendorff K., Westley C. B., Gallardo C. S. Observations on the production of purple pigments in the egg capsules, hypobranchial and reproductive glands from seven species of Muricidae (Gastropoda: Mollusca). Invertebr Reprod Dev: 2004; 46 93 102 (Pubitemid 40763999)
43. Edwards V., Benkendorff K., Young F. Marine compounds selectively induce apoptosis in female reproductive cancer cells but not in primary-derived human reproductive granulosa cells. Mar Drugs: 2012; 10 64 83
44. Westley C. B., McIver C. M., Abbott C. A., Le Leu R. K., Benkendorff K. Enhanced acute apoptotic response to azoxymethane-induced DNA damage in the rodent colonic epithelium by Tyrian purple precursors: a potential colorectal cancer chemopreventative. Cancer Biol Ther: 2010; 9 371 379
45. Bayer A. Ueber die Verbindungen der Indigogruppe. Chem Ber: 1883; 16 2188 2204
46. Russel G. A., Kaupp G. Oxidation of carbanions. IV. Oxidation of indoxyl to indigo in basic solution. J Am Chem Soc: 1969; 91 3851 3859
47. Clarck R. JH, Cooksey C. J. Bromoindirubins: the synthesis and properties of minor components of Tyrian purple and the composition of the colorant from Nucella lapillus. J Soc Dyers Colour: 1997; 113 316 321 (Pubitemid 127639250)
48. Sandmeyer T. Ueber Isonitrosoacetanilide und deren Kondensation zu Isatinen. Helv Chim Acta: 1919; 2 234 242
49. Zhang A., Yu M., Lan T., Liu Z., Mao Z. Novel synthesis of 4- or 6-substituted indirubin derivatives. Synth Commun: 2010; 40 3125 3134
50. Tanoue Y., Ikoma Y., Kai N., Nagai T. Synthesis of halogenoindirubins. J Heterocyclic Chem: 2009; 46 1016 1018
51. Polychronopoulos P., Magiatis P., Skaltsounis A. L., Myrianthopoulos V., Mikros E., Tarricone A., Musacchio A., Roe S. M., Pearl L., Leost M., Greengard P., Meijer L. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem: 2004; 47 935 946 (Pubitemid 38176796)
52. Saito H., Tabata K., Hanada S., Kanda Y., Suzuki T., Miyairi S. Synthesis of methoxy- and bromo-substituted indirubins and their activities on apoptosis induction in human neuroblastoma cells. Bioorg Med Chem Lett: 2011; 21 5370 5373
53. Beauchard A., Laborie H., Rouillard H., Lozach O., Ferandin Y., Le Guével R., Guguen-Guillouzo C., Meijer L., Besson T., Thiéry V. Synthesis and kinase inhibitory activity of novel substituted indigoids. Bioorg Med Chem: 2009; 17 6257 6263
54. Beauchard A., Ferandin Y., Frère S., Lozach O., Blairvacq M., Meijer L., Thiéry V., Besson T. Synthesis of novel 5-substituted indirubins as protein kinases inhibitors. Bioorg Med Chem: 2006; 14 6434 6443
55. Park E. J., Choi S. J., Kim Y. C., Lee S. H., Park S. W., Lee S. K. Novel small molecule activators of beta-catenin-mediated signaling pathway: structure-activity relationships of indirubins. Bioorg Med Chem Lett: 2009; 19 2282 2284
56. Moon M. J., Lee S. K., Lee J. W., Song W. K., Kim S. W., Kim J. I., Cho C., Choi S. J., Kim Y. C. Synthesis and structure-activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities. Bioorg Med Chem: 2006; 14 237 246 (Pubitemid 41635486)
57. Choi S. J., Lee J. E., Jeong S. Y., Im I., Lee S. D., Lee E. J., Lee S. K., Kwon S. M., Ahn S. G., Yoon J. H., Han S. Y., Kim J. I., Kim Y. C. 5-5-substituted indirubin-3-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem: 2010; 54 3696 3706
58. Choi S. J., Moon M. J., Lee S. D., Choi S. U., Han S. Y., Kim Y. C. Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells. Bioorg Med Chem Lett: 2010; 20 2033 2037
59. Vougogiannopoulou K., Ferandin Y., Bettayeb K., Myrianthopoulos V., Lozach O., Fan Y., Johnson C. H., Magiatis P., Skaltsounis A. L., Mikros E., Meijer L. Soluble 3,6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase 3 alter circadian period. J Med Chem: 2008; 51 6421 6431
60. Jautelat R., Brumby T., Schäfer M., Briem H., Eisenbrand G., Schwahn S., Krüger M., Lücking U., Prien O., Siemeister G. From the insoluble dye indirubin towards highly active, soluble CDK2-inhibitors. Chembiochem: 2005; 6 531 540 (Pubitemid 40868142)
61. Ferandin Y., Bettayeb K., Kritsanida M., Lozach O., Polychronopoulos P., Magiatis P., Skaltsounis A. L., Meijer L. 3-Substituted 7-halogenoindirubins, a new class of cell death inducing agents. J Med Chem: 2006; 49 4638 4649 (Pubitemid 44162690)
62. Libnow S., Methling K., Hein M., Michalik D., Harms M., Wende K., Flemming A., Köckerling M., Reinke H., Bednarski P. J., Lalk M., Langer P. Synthesis of indirubin-N-glycosides and their anti-proliferative activity against human cancer cell lines. Bioorg Med Chem: 2008; 16 5570 5583 (Pubitemid 351694473)
63. Libnow S., Hein M., Langer P. The first N -glycosylated indoxyls and their application to the synthesis of indirubin- N -glycosides (purple sugars). Synlett: 2009; 2009 221 224
64. Kritsanida M., Magiatis P., Skaltsounis A. L., Peng Y., Li P., Wennogle L. P. Synthesis and antiproliferative activity of 7-azaindirubin-3-oxime, a 7-aza isostere of the natural indirubin pharmacophore. J Nat Prod: 2009; 72 2199 2202
65. Wang Z. H., Li W. Y., Li F. L., Zhang L., Hua W. Y., Cheng J. C., Yao Q. Z. Synthesis and antitumor activity of 7-azaindirubin. Chin Chem Lett: 2009; 20 542 544
66. Cheng X., Rasqué P., Vatter S., Merz K. H., Eisenbrand G. Synthesis and cytotoxicity of novel indirubin-5-carboxamides. Bioorg Med Chem: 2010; 18 4509 4515
67. Schwartz P. A., Murray B. W. Protein kinase biochemistry and drug discovery. Bioorg Chem: 2011; 39 192 210
68. Cohen P. Protein kinasesthe major drug targets of the twenty-first century? Nat Rev Drug Discov: 2002; 1 309 315 (Pubitemid 37361447)
69. Hunter T., Cooper J. A. Protein-tyrosine kinases. Annu Rev Biochem: 1985; 54 897 930 (Pubitemid 15073667)
70. Xingi E., Smirlis D., Myrianthopoulos V., Magiatis P., Grant K. M., Meijer L., Mikros E., Skaltsounis A. L., Soteriadou K. 6-Br-5-methylindirubin-3- oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: exploitation of GSK-3 for treating leishmaniasis. Int J Parasitol: 2009; 39 1289 1303
71. Ribas J., Bettayeb K., Ferandin Y., Knockaert M., Garrofé-Ochoa X., Totzke F., Schächtele C., Mester J., Polychronopoulos P., Magiatis P., Skaltsounis A. L., Boix J., Meijer L. 7-Bromoindirubin-3-oxime induces caspase-independent cell death. Oncogene: 2006; 25 6304 6318 (Pubitemid 44564746)
72. Manning G., Whyte D. B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science: 2002; 298 1912 1934 (Pubitemid 35425239)
73. Norbury C., Nurse P. Animal cell cycles and their control. Annu Rev Biochem: 1992; 61 441 470
74. Cicenas J., Valius M. The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol: 2011; 137 1409 1418
75. Galons H., Oumata N., Meijer L. Cyclin-dependent kinase inhibitors: a survey of recent patent literature. Expert Opin Ther Pat: 2010; 20 377 404
76. Rizzolio F., Tuccinardi T., Caligiuri I., Lucchetti C., Giordano A. CDK inhibitors: from the bench to clinical trials. Curr Drug Targets: 2010; 11 279 290
77. Knockaert M., Greengard P., Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci: 2002; 23 417 425 (Pubitemid 35247771)
78. Lim A. C., Qi R. Z. Cyclin-dependent kinases in neural development and degeneration. J Alzheimers Dis: 2003; 5 329 335 (Pubitemid 37411781)
79. Martinez A., Castro A., Dorronsoro I., Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev: 2002; 22 373 384 (Pubitemid 34620473)
80. Boutajangout A., Sigurdsson E. M., Krishnamurthy P. K. Tau as a therapeutic target for Alzheimers disease. Curr Alzheimer Res: 2011; 8 666 677
81. Huang H-C, OBrien W. T., Klein P. S. Targeting glycogen synthase kinase-3 in Alzheimers disease. Drug Discov Today Ther Strateg: 2006; 3 613 619 (Pubitemid 46083337)
82. Koistinaho J., Malm T., Goldsteins G. Glycogen synthase kinase-3 β: a mediator of inflammation in Alzheimers disease? Int J Alzheimers Dis: 2011; 2011 129753
83. Picchini A. M., Manji H. K., Gould T. D. GSK-3 and neurotrophic signaling: Novel targets underlying the pathophysiology and treatment of mood disorders? Drug Discov Today Dis Mech: 2004; 1 419 428 (Pubitemid 41128945)
84. Freyberg Z., Ferrando S. J., Javitch J. A. Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry: 2010; 167 388 396
85. Hoeppner L. H., Secreto F. J., Westendorf J. J. Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets: 2009; 13 485 496
86. Ougolkov A. V., Billadeau D. D. Targeting GSK-3: a promising approach for cancer therapy? Future Oncol: 2006; 2 91 100
87. Hardt S. E., Sadoshima J. Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. Circ Res: 2002; 90 1055 1063 (Pubitemid 34627903)
88. Phukan S., Babu V. S., Kannoji A., Hariharan R., Balaji V. N. GSK3beta: role in therapeutic landscape and development of modulators. Br J Pharmacol: 2010; 160 1 19
89. GSK-3 inhibitor IX (361550) product details, specifications and data sheets. http://www.merckmillipore.com/greece/life-science-research/gsk-3- inhibitor-ix/EMD-BIO-361550/p-R66b.s1LTrMAAAEWx2EfVhTm
90. Han S-Y, Ahn J. H., Shin C. Y., Choi S. U. Effects of indirubin derivatives on the FLT3 activity and growth of acute myeloid leukemia cell lines. Drug Develop Res: 2010; 71 221 227
91. Luo C., Laaja P. Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs. Drug Discov Today: 2004; 9 268 275 (Pubitemid 38328513)
92. Zahler S., Tietze S., Totzke F., Kubbutat M., Meijer L., Vollmar A. M., Apostolakis J. Inverse in silico screening for identification of kinase inhibitor targets. Chem Biol: 2007; 14 1207 1214 (Pubitemid 350102244)
93. Forde J. E., Dale T. C. Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci: 2007; 64 1930 1944 (Pubitemid 47094432)
94. Toledo E. M., Colombres M., Inestrosa N. C. Wnt signaling in neuroprotection and stem cell differentiation. Prog Neurobiol: 2008; 86 281 296
95. Yao H., Ashihara E., Maekawa T. Targeting the Wnt/ β -catenin signaling pathway in human cancers. Expert Opin Ther Targets: 2011; 15 873 887
96. Schnitzer S. E., Schmid T., Zhou J., Eisenbrand G., Brüne B. Inhibition of GSK3beta by indirubins restores HIF-1alpha accumulation under prolonged periods of hypoxia/anoxia. FEBS Lett: 2005; 579 529 533 (Pubitemid 40092439)
97. Sinha D., Wang Z., Ruchalski K. L., Levine J. S., Krishnan S., Lieberthal W., Schwartz J. H., Borkan S. C. Lithium activates the Wnt and phosphatidylinositol 3-kinase Akt signaling pathways to promote cell survival in the absence of soluble survival factors. Am J Physiol Renal Physiol: 2005; 288 F703 F713 (Pubitemid 40381737)
98. Lee M. J., Kim M. Y., Mo J. S., Ann E. J., Seo M. S., Hong J. A., Kim Y. C., Park H. S. Indirubin-3-monoxime, a derivative of a Chinese anti-leukemia medicine, inhibits Notch1 signaling. Cancer Lett: 2008; 265 215 225
99. Yoon J. H., Kim S. A., Kwon S. M., Park J. H., Park H. S., Kim Y. C., Yoon J. H., Ahn S. G. 5-Nitro-indirubinoxime induces G1 cell cycle arrest and apoptosis in salivary gland adenocarcinoma cells through the inhibition of Notch-1 signaling. Biochim Biophys Acta: 2010; 1800 352 358
100. Aggarwal B. B., Sethi G., Ahn K. S., Sandur S. K., Pandey M. K., Kunnumakkara A. B., Sung B., Ichikawa H. Targeting signal-transducer-and- activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann NY Acad Sci: 2006; 1091 151 169 (Pubitemid 47092233)
101. Song L., Turkson J., Karras J. G., Jove R., Haura E. B. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene: 2003; 22 4150 4165 (Pubitemid 36876236)
102. Zhang X., Song Y., Wu Y., Dong Y., Lai L., Zhang J., Lu B., Dai F., He L., Liu M., Yi Z. Indirubin inhibits tumor growth by antitumor angiogenesis via blocking VEGFR2-mediated JAK/STAT3 signaling in endothelial cell. Int J Cancer: 2011; 129 2502 2511
103. Schwaiberger A. V., Heiss E. H., Cabaravdic M., Oberan T., Zaujec J., Schachner D., Uhrin P., Atanasov A. G., Breuss J. M., Binder B. R., Dirsch V. M. Indirubin-3-monoxime blocks vascular smooth muscle cell proliferation by inhibition of signal transducer and activator of transcription 3 signaling and reduces neointima formation in vivo. Arterioscler Thromb Vasc Biol: 2010; 30 2475 2481
104. Menschikowski M., Hagelgans A., Hempel U., Siegert G. Glycogen synthase kinase-3beta negatively regulates group IIA phospholipase A2 expression in human aortic smooth muscle and HepG2 hepatoma cells. FEBS Lett: 2004; 577 81 86 (Pubitemid 39452364)
105. Beurel E., Jope R. S. Differential regulation of STAT family members by glycogen synthase kinase-3. J Biol Chem: 2008; 283 21934 21944
106. Kawakami F., Yamaguchi A., Suzuki K., Yamamoto T., Ohtsuki K. Biochemical characterization of phospholipids, sulfatide and heparin as potent stimulators for autophosphorylation of GSK-3beta and the GSK-3beta-mediated phosphorylation of myelin basic protein in vitro. J Biochem: 2008; 143 359 367 (Pubitemid 351363948)
107. Gu Y. C., Li G. L., Yang Y. P., Fu J. P., Li C. Z. Synthesis of some halogenated indirubin derivatives. Acta Pharmaceutica Sinica: 1989; 24 629 632
108. Davies T. G., Tunnah P., Meijer L., Marko D., Eisenbrand G., Endicott J. A., Noble M. EM. Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulfonate. Structure: 2001; 9 389 397 (Pubitemid 32497266)
109. Bertrand J. A., Thieffine S., Vulpetti A., Cristiani C., Valsasina B., Knapp S., Kalisz H. M., Flocco M. Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors. J Mol Biol: 2003; 333 393 407 (Pubitemid 37188580)
110. Lather V., Kristam R., Saini J. S., Kristam R., Karthikeyan N. A., Balaji V. N. QSAR models for prediction of glycogen synthase kinase-3β inhibitory activity derivatives. QSAR Comb Sci: 2008; 27 718 728
111. Toledo E. M., Colombres M., Inestrosa N. C. Wnt signaling in neuroprotection and stem cell differentiation. Prog Neurobiol: 2008; 86 281 296
112. Sineva G. S., Pospelov V. A. Inhibition of GSK3beta enhances both adhesive and signalling activities of beta-catenin in mouse embryonic stem cells. Biol Cell: 2010; 102 549 560
113. Ko K. H., Holmes T., Palladinetti P., Song E., Nordon R., OBrien T. A., Dolnikov A. GSK-3β inhibition promotes engraftment of ex vivo -expanded hematopoietic stem cells and modulates gene expression. Stem Cells: 2011; 29 108 118
114. Ogawa K., Nishinakamura R., Iwamatsu Y., Shimosato D., Niwa H. Synergistic action of Wnt and LIF in maintaining pluripotency of mouse ES cells. Biochem Biophys Res Commun: 2006; 343 159 166
115. Cartwright P., McLean C., Sheppard A., Rivett D., Jones K., Dalton S. LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism. Development: 2005; 132 885 896 (Pubitemid 40484924)
116. Holmes T., OBrien T. A., Knight R., Lindeman R., Shen S., Song E., Symonds G., Dolnikov A. Glycogen synthase kinase-3beta inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth. Stem Cells: 2008; 26 1288 1297
117. Jiang J., Zhao M., Zhang A., Yu M., Lin X., Wu M., Wang X., Lu H., Zhu S., Yu Y., Mao Z., Han W. Characterization of a GSK-3 inhibitor in culture of human cord blood primitive hematopoietic cells. Biomed Pharmacother: 2010; 64 482 486
118. Manceur A. P., Tseng M., Holowacz T., Witterick I., Weksberg R., McCurdy R. D., Warsh J. J., Audet J. Inhibition of glycogen synthase kinase-3 enhances the differentiation and reduces the proliferation of adult human olfactory epithelium neural precursors. Exp Cell Res: 2011; 317 2086 2098
119. Krause U., Harris S., Green A., Ylostalo J., Zeitouni S., Lee N., Gregory C. A. Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy. Proc Natl Acad Sci USA: 2010; 107 4147 4152
120. Wang F. S., Ko J. Y., Weng L. H., Yeh D. W., Ke H. J., Wu S. L. Inhibition of glycogen synthase kinase-3beta attenuates glucocorticoid-induced bone loss. Life Sci: 2009; 85 685 692
121. Gattinoni L., Zhong X. S., Palmer D. C., Ji Y., Hinricks C. S., Yu Z., Wresinski C., Boni A., Cassard L., Garvin L. M., Paulos C. H., Muranski P., Restifo N. P. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med: 2009; 15 808 813
122. Zaragosi L. E., Wdziekonski B., Fontaine C., Villageois P., Peraldi P., Dani C. Effects of GSK3 inhibitors on in vitro expansion and differentiation of human adipose-derived stem cells into adipocytes. BMC Cell Biol: 2008; 9 11
123. Lluis F., Pedone E., Pepe S., Cosma M. P. Periodic activation of Wnt/beta-catenin signaling enhances somatic cell reprogramming mediated by cell fusion. Cell Stem Cell: 2008; 3 493 507
124. Ullmann U., Gilles C., De Rycke M., Van de Velde H., Sermon K., Liebaers I. GSK-3-specific inhibitor-supplemented hESC medium prevents the epithelial-mesenchymal transition process and the up-regulation of matrix metalloproteinases in hESCs cultured in feeder-free conditions. Mol Hum Reprod: 2008; 14 169 179 (Pubitemid 351404890)
125. Ikonomou L., Geras-Raaka E., Raaka B. M., Gershengorn M. C. β -catenin signaling in mesenchymal islet-derived precursor cells. Cell Prolif: 2008; 41 474 491 (Pubitemid 351692943)
126. Umehara H., Kimura T., Ohtsuka S., Nakamura T., Kitajima K., Ikawa M., Okabe M., Niwa H., Nakano T. Efficient derivation of embryonic stem cells by inhibition of glycogen synthase kinase-3. Stem Cells: 2007; 25 2705 2711 (Pubitemid 350127854)
127. Yang W., Wei W., Shi C., Zhu J., Ying W., Shen Y., Ye X., Fang L., Duo S., Che J., Shen H., Ding S., Deng H. Pluripotin combined with leukemia inhibitory factor greatly promotes the derivation of embryonic stem cell lines from refractory strains. Stem Cells: 2009; 27 383 389
128. Doungpunta J., Sathi A., Sathanawongs A., Jarujinda Y., Oranratnachai A. Fivefold increase in derivation rates of mouse embryonic stem cells after supplementation of the media with multiple factors. Theriogenology: 2009; 72 232 242
129. Wen J., Liu J., Song G., Liu L., Tang B., Li Z. Effects of 6-bromoindirubin-3-oxime on the maintenance of pluripotency of porcine embryonic germ cells in combination with stem cell factor, leukemia inhibitory factor and fibroblast growth factor. Reproduction: 2010; 139 1039 1046
130. Sato H., Amagai K., Shimizukawa R., Tamai Y. Stable generation of serum- and feeder-free embryonic stem cell-derived mice with full germline-competency by using a GSK3 specific inhibitor. Genesis: 2009; 47 414 422
131. Ribas J., Yuste V. J., Garrofé-Ochoa X., Meijer L., Esquerda J. E., Boix J. 7-Bromoindirubin-3-oxime uncovers a serine protease-mediated paradigm of necrotic cell death. Biochem Pharmacol: 2008; 76 39 52
132. Nam S., Buettner R., Turkson J., Kim D., Cheng J. Q., Muehlbeyer S., Hippe F., Vatter S., Merz K. H., Eisenbrand G., Jove R. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci USA: 2005; 102 5998 6003 (Pubitemid 40594244)
133. Liu L., Nam S., Tian Y., Wu J., Wang Y., Scuto A., Polychronopoulos P., Magiatis P., Skaltsounis L., Jove R. 6-Bromoindirubin-3-oxime inhibits JAK/STAT3 signaling and induces apoptosis in human melanoma cells. Cancer Res: 2011; 71 3972 3979
134. Chebel A., Kagialis-Girard S., Catallo R., Chien W. W., Mialou V., Domenech C., Badiou C., Tigaud I., Ffrench M. Indirubin derivatives inhibit malignant lymphoid cell proliferation. Leuk Lymphoma: 2009; 50 2049 2060
135. Song E. Y., Palladinetti P., Klamer G., Ko K. H., Lindeman R., OBrien T. A., Dolnikov A. Glycogen synthase kinase3β inhibitors suppress leukemia cell growth. Exp Hematol: 2010; 38 908 921 (e1)
136. Wang Z., Smith K. S., Murphy M., Piloto O., Somervaille T. C., Cleary M. L. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature: 2008; 455 1205 1209
137. Williams S. P., Nowicki M. O., Liu F., Press R., Godlewski J., Abdel-Rasoul M., Kaur B., Fernandez S. A., Chiocca E. A., Lawler S. E. Indirubins decrease glioma invasion by blocking migratory phenotypes in both the tumor and stromal endothelial cell compartments. Cancer Res: 2011; 71 5374 5380
138. Bilsland A. E., Hoare S., Stevenson K., Plumb J., Gomez-Roman N., Cairney C., Burns S., Lafferty-White K., Roffey J., Hammonds T., Keith W. N. Dynamic telomerase gene suppression via network effects of GSK3 inhibition. PLoS ONE: 2009; 4 e6459
139. Cheng H., Woodgett J., Maamari M., Force T. Targeting GSK-3 family members in the heart: a very sharp double-edged sword. J Mol Cell Cardiol: 2011; 51 607 613
140. Tateishi K., Ashihara E., Honsho S., Takehara N., Nomura T., Takahashi T., Ueyama T., Yamagishi M., Yaku H., Matsubara H., Oh H. Human cardiac stem cells exhibit mesenchymal features and are maintained through Akt/GSK-3beta signaling. Biochem Biophys Res Commun: 2007; 352 635 641 (Pubitemid 44880302)
141. Tseng A. S., Engel F. B., Keating M. T. The GSK-3 inhibitor BIO promotes proliferation in mammalian cardiomyocytes. Chem Biol: 2006; 13 957 963 (Pubitemid 44389934)
142. Novoyatleva T., Diehl F., van Amerongen M. J., Patra C., Ferrazzi F., Bellazzi R., Engel F. B. TWEAK is a positive regulator of cardiomyocyte proliferation. Cardiovasc Res: 2010; 85 681 690
143. Qyang Y., Martin-Puig S., Chiravuri M., Chen S., Xu H., Bu L., Jiang X., Lin L., Granger A., Moretti A., Caron L., Wu X., Clarke J., Taketo M. M., Laugwitz K. L., Moon R. T., Gruber P., Evans S. M., Ding S., Chien K. R. The renewal and differentiation of Isl1+ cardiovascular progenitors are controlled by a Wnt/beta-catenin pathway. Cell Stem Cell: 2007; 1 165 179 (Pubitemid 47224618)
144. Bu L., Jiang X., Martin-Puig S., Caron L., Zhu S., Shao Y., Roberts D. J., Huang P. L., Domian I. J., Chien K. R. Human ISL1 heart progenitors generate diverse multipotent cardiovascular cell lineages. Nature: 2009; 460 113 117
145. Valerio A., Bertolotti P., Delbarba A., Perego C., Dossena M., Ragni M., Spano P., Carruba M. O., De Simoni M. G., Nisoli E. Glycogen synthase kinase-3 inhibition reduces ischemic cerebral damage, restores impaired mitochondrial biogenesis and prevents ROS production. J Neurochem: 2011; 116 1148 1159
146. Skardelly M., Gaber K., Schwarz J., Milosevic J. Neuroprotective effects of the beta-catenin stabilization in an oxygen- and glucose-deprived human neural progenitor cell culture system. Int J Dev Neurosci: 2011; 29 543 547
147. Barillas R., Friehs I., Cao-Danh H., Martinez J. F., del Nido P. J. Inhibition of glycogen synthase kinase 3β improves tolerance to ischemia in hypertrophied hearts. Ann Thorac Surg: 2007; 84 126 133 (Pubitemid 46921104)
148. Trivedi C. M., Luo Y., Yin Z., Zhang M., Zhu W., Wang T., Floss T., Goettlicher M., Noppinger P. R., Wurst W., Ferrari V. A., Abrams C. S., Gruber P. J., Epstein J. A. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med: 2007; 13 324 331 (Pubitemid 46376684)
149. Lin C. L., Wang J. Y., Huang Y. T., Kuo Y. H., Surendran K., Wang F. S. Wnt/beta-catenin signaling modulates survival of high glucose-stressed mesangial cells. J Am Soc Nephrol: 2006; 17 2812 2820 (Pubitemid 44484671)
150. Kuure S., Popsueva A., Jakobson M., Sainio K., Sariola H. Glycogen synthase kinase-3 inactivation and stabilization of beta-catenin induce nephron differentiation in isolated mouse and rat kidney mesenchymes. J Am Soc Nephrol: 2007; 18 1130 1139 (Pubitemid 46536899)
151. Wang Y., Huang W. C., Wang C. Y., Tsai C. C., Chen C. L., Chang Y. T., Kai J. I., Lin C. F. Inhibiting glycogen synthase kinase-3 reduces endotoxaemic acute renal failure by down-regulating inflammation and renal cell apoptosis. Br J Pharmacol: 2009; 157 1004 1013
152. Mussmann R., Geese M., Harder F., Kegel S., Andag U., Lomow A., Burk U., Onichtchouk D., Dohrmann C., Austen M. Inhibition of GSK3 promotes replication and survival of pancreatic beta cells. J Biol Chem: 2007; 282 12030 12037 (Pubitemid 47100714)
153. Itoh T., Kamiya Y., Okabe M., Tanaka M., Miyajima A. Inducible expression of Wnt genes during adult hepatic stem/progenitor cell response. FEBS Lett: 2009; 583 777 781
154. Meijer L., Flajolet M., Greengard P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci: 2004; 25 471 480 (Pubitemid 39149703)
155. Lim Y. W., Yoon S. Y., Choi J. E., Kim S. M., Lee H. S., Choe H., Lee S. C., Kim D. H. Maintained activity of glycogen synthase kinase-3beta despite of its phosphorylation at serine-9 in okadaic acid-induced neurodegenerative model. Biochem Biophys Res Commun: 2010; 395 207 212
156. Martin L., Magnaudeix A., Esclaire F., Yardin C., Terro F. Inhibition of glycogen synthase kinase-3beta downregulates total tau proteins in cultured neurons and its reversal by the blockade of protein phosphatase-2A. Brain Res: 2009; 1252 66 75
157. Martin L., Page G., Terro F. Tau phosphorylation and neuronal apoptosis induced by the blockade of PP2A preferentially involve GSK3 β Neurochem Int: 2011; 59 235 250
158. Martin L., Magnaudeix A., Wilson C. M., Yardin C., Terro F. The new indirubin derivative inhibitors of glycogen synthase kinase-3, 6-BIDECO and 6-BIMYEO, prevent tau phosphorylation and apoptosis induced by the inhibition of protein phosphatase-2A by okadaic acid in cultured neurons. J Neurosci Res: 2011; 89 1802 1811
159. Hongisto V., Smeds N., Brecht S., Herdegen T., Courtney M. J., Coffey E. T. Lithium blocks the c-Jun stress response and protects neurons via its action on glycogen synthase kinase 3. Mol Cell Biol: 2003; 23 6027 6036 (Pubitemid 37013083)
160. Nguyen T. B., Lucero G. R., Chana G., Hult B. J., Tatro E. T., Masliah E., Grant I., Achim C. L., Everall I. P. HIV Neurobehavioral Research Group Glycogen synthase kinase-3beta (GSK-3beta) inhibitors AR-A014418 and B6B3O prevent human immunodeficiency virus-mediated neurotoxicity in primary human neurons. J Neurovirol: 2009; 15 434 438
161. Meares G. P., Mines M. A., Beurel E., Eom T. Y., Song L., Zmijewska A. A., Jope R. S. Glycogen synthase kinase-3 regulates endoplasmic reticulum (ER) stress-induced CHOP expression in neuronal cells. Exp Cell Res: 2011; 317 1621 1628
162. Magiatis P., Polychronopoulos P., Skaltsounis A. L., Lozach O., Meijer L., Miller D. B., OCallaghan J. P. Indirubins deplete striatal monoamines in the Intact and MPTP-treated mouse brain and block kainate-induced striatal astrogliosis. Neurotoxicol Teratol: 2010; 32 212 219
163. Kim W. Y., Zhou F. Q., Zhou J., Yokota Y., Wang Y. M., Yoshimura T., Kaibuchi K., Woodgett J. R., Anton E. S., Snider W. D. Essential roles for GSK-3s and GSK-3-primed substrates in neurotrophin induced and hippocampal axon growth. Neuron: 2006; 52 981 996 (Pubitemid 44909402)
164. Alabed Y. Z., Pool M., Ong Tone S., Sutherland C., Fournier A. E. GSK-3β regulates myelin dependent axon outgrowth inhibition through CRMP4. J Neurosci: 2010; 30 5635 5643
165. Xingi E., Smirlis D., Myrianthopoulos V., Magiatis P., Grant K. M., Meijer L., Mikros E., Skaltsounis A. L., Soteriadou K. 6-Br-5methylindirubin- 3oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: exploitation of GSK-3 for treating leishmaniasis. Int J Parasitol: 2009; 39 1289 1303
166. Grant K. M., Dunion M. H., Yardley V., Skaltsounis A. L., Marko D., Eisenbrand G., Croft S. L., Meijer L., Mottram J. C. Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity. Antimicrob Agents Chemother: 2004; 48 3033 3042 (Pubitemid 38989172)
167. Mahendra A., Vivek K., Parameswaran S., Mohan C. G. Homology modeling and atomic level binding study of Leishmania MAPK with inhibitors. J Mol Model: 2010; 16 475 488
168. Krivogorsky B., Grundt P., Yolken R., Jones-Brando L. Inhibition of Toxoplasma gondii by indirubin and tryptanthrin analogs. Antimicrob Agents Chemother: 2008; 52 4466 4469
169. Fabres A., de Andrade C. P., Guizzo M., Sorgine M. HF, de O Paiva-Silva G., Masuda A., da Silva Vaz I., Logullo C. Effect of GSK-3 activity, enzymatic inhibition and gene silencing by RNAi on tick oviposition and egg hatching. Parasitology: 2010; 137 1 10
170. Pohjanvirta R., Tuomisto J. Short-term toxicity of 2,3,7,8- tetrachlorodibenzo-p-dioxin in laboratory animals: effects, mechanisms, and animal models. Pharmacol Rev: 1994; 46 483 549
171. Sugihara K., Okayama T., Kitamura S., Yamashita K., Yasuda M., Miyairi S., Minobe Y., Ohta S. Comparative study of aryl hydrocarbon receptor ligand activities of six chemicals in vitro and in vivo. Arch Toxicol: 2008; 82 5 11
172. Peter Guengerich F., Martin M. V., McCormick W. A., Nguyen L. P., Glover E., Bradfield C. A. Aryl hydrocarbon receptor response to indigoids in vitro and in vivo. Arch Biochem Biophys: 2004; 423 309 316 (Pubitemid 38328440)
173. Adachi J., Mori Y., Matsui S., Matsuda T. Comparison of gene expression patterns between 2,3,7,8-tetrachlorodibenzo-p-dioxin and a natural arylhydrocarbon receptor ligand, indirubin. Toxicol Sci: 2004; 80 161 169 (Pubitemid 38967407)
174. Schlezinger J. J., Liu D., Farago M., Seldin D. C., Belguise K., Sonenshein G. E., Sherr D. H. A role for the aryl hydrocarbon receptor in mammary gland tumorigenesis. Biol Chem: 2006; 387 1175 1187 (Pubitemid 44402063)
175. Puga A., Barnes S. J., Dalton T. P., Chang C., Knudsen E. S., Maier M. A. Aromatic hydrocarbon receptor interaction with the retinoblastoma protein potentiates repression of E2F-dependent transcription and cell cycle arrest. J Biol Chem: 2000; 275 2943 2950 (Pubitemid 30082071)
176. Korzeniewski N., Wheeler S., Chatterjee P., Duensing A., Duensing S. A novel role of the aryl hydrocarbon receptor (AhR) in centrosome amplification implications for chemoprevention. Mol Cancer: 2010; 9 153